Date:2/18/2010

used on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulato
'/>"/>

SOURCE Cornerstone Therapeutics Inc. Copyright©2010 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
2. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
3. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
4. Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
5. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
6. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
7. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
8. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
9. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
10. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
11. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics